Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715586 | 0.78 | PDE5A (0.57) | CSF1RCHKAPDE5ACYP1A2CYP2C9 | |
| SCHEMBL148298 | 0.75 | PDE5A (0.65) | PDE5A | |
| SCHEMBL23601070 | 0.75 | CSF1R (0.68) | CSF1RCHKAPDE5A | |
| SCHEMBL5082461 | 0.73 | CSF1R (0.51) | CSF1RCSNK2A2CSNK2BCHKACYP1A2 | |
| SCHEMBL432877 | 0.68 | MEN1 (0.57) | CSF1RPDE5ACYP1A2CYP2C9CYP3A4 | |
| SCHEMBL23601802 | 0.67 | CSF1R (0.60) | CSF1RCHKA | |
| SCHEMBL30961034 | 0.67 | CSF1R (0.60) | CSF1RCHKA | |
| SCHEMBL30014151 | 0.66 | EGFR (0.59) | CSF1RCSNK2A2CSNK2BCHKAPDE5A | |
| SCHEMBL23577274 | 0.66 | EGFR (0.59) | CSF1RCSNK2A2CSNK2BCHKAPDE5A | |
| SCHEMBL3123760 | 0.66 | CSF1R (1.00) | CSF1RCHKASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | COMBINATORX, INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20030207852-A1 | Treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2003-11-06 | — | — | US | disclosed |
| US-6593313-B2 | Administering to the vagina, vulvar area or urethra of the female a pharmaceutical formulation comprises a vasoactive agent selected from natural or synthetic prostaglandins, endothelial derived relaxation factors, hypotensive agents | VIVUS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1027057-A4 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | VIVUS INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6472434-B1 | VASOACTIVE AGENT IS ADMINISTERED TO THE VAGINA, VULVAR AREA OR URETHRA OF THE INDIVIDUAL UNDERGOING TREATMENT. SUITABLE VASOACTIVE AGENTS ARE VASODILATORS, INCLUDING NATURALLY OCCURRING PROSTAGLANDINS, SYNTHETIC PROSTAGLANDIN DERIVATIVES, | VIVUS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20010051656-A1 | Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | TNF, PYGM, IL6 | CSF1R 2112/4885CSNK2A2 550/4885CSNK2B 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.